Drug Pipeline News

Backed by phase 3 data showing an overall success rate of 58.5% versus 60.2% for IV imipenem-cilastatin, tebipenem HBr has been approved by the FDA as the first oral carbapenem antibiotic for the treatment of complicated urinary tract infections in the US.

Presented at SLEEP 2026, NIRVANA data show a consistent elinzanetant treatment signal across three sleep measurement modalities, extending earlier OASIS trial findings on patient-reported sleep outcomes in menopausal women.

The FDA has approved Wockhardt’s cefepime and zidebactam, a novel intravenous antibiotic that targets multiple penicillin-binding proteins to treat adults with complicated urinary tract infections.

An at-home menstrual blood diagnostic platform in development may enable earlier, noninvasive detection of endometriosis.

During clinical validation done by the company, Unity Confirm demonstrated 100% concordance with known fetal outcomes and invasive diagnostic results in 16 samples.

These are the top 5 headlines you might have missed in April 2026 from Contemporary OB/GYN.

The expanded label to include use during pregnancy complicated by type 1 diabetes mellitus is based on data from the CIRCUIT trial.

Utepreva LLC has launched a proprietary, FDA-cleared endometrial sampler that combines suction, disruption, and absorption to improve tissue yield in 20-second office procedures.

The letter from the federal agency allows further phase 2 development for refisolone under an investigational new drug application.

Ramu Perni highlights how the "one tube" workflow streamlines obstetric practices by enabling add-on RBC and platelet antigen tests.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

The FDA cleared the Onclarity HPV Self-Collection Kit, allowing patients to collect samples at home for processing via the FDA-cleared BD Onclarity HPV Assay and BD COR System.

The Ringza slow-release vaginal ring has launched in Canada and is designed to be re-used for up to 1 year.

Researchers developed a porous membrane organ-on-a-chip that replicates the human cervix to study how the microbiome and immune system interact with chlamydia and gonorrhea.

Take a look back at some of the top FDA-related news items—from de Novo clearances to advancing trials—that Contemporary OB/GYN covered in the first quarter of 2026.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

From FDA regulatory updates for products related to women's health, to a preview of upcoming annual meetings and conferences, we keep you updated on what's to come in Q2 of 2026.

Livi is a single-use, soft polyurethane foam device cleared by the FDA to absorb semen and vaginal discharge within approximately 60 seconds.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

ENDO-205 is EndoCyclic Therapeutics' lead program and consists of a first-in-class, non-hormonal targeted epeptide therapeutic for endometriosis, according to the company.

Among 2029 women in Scandinavian countries who were followed up for 14 years, vaccine effectiveness was 100%.

Dardik explains how De Novo-cleared AI identifies preterm birth risk in low-risk pregnancies through whole-image analysis.

Kevin Benson highlighted that the TITAN 2 study demonstrates the Altaviva ITNM system as a safe, minimally invasive, and durable solution for real-world patients who have failed prior overactive bladder treatments.

Raquel Dardik explains how the FDA-cleared Delivery Date AI uses unbiased image analysis to provide a precise predicted delivery date without disrupting existing clinical workflows.